StockUS listing USABSINASDAQHealthcareEarnings Deterioration

Absci Corp(ABSI) Stock Analysis | Healthcare

USD --+0.00%
Reward38Moderate
Risk73High
75%Data
Revenue down 20% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.30Bn
Reward Ratingⓘ38 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ73 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ABSI to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Absci Corp?

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.

AI Brief Pro

The brief on Absci Corp

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Absci Corp?

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.30B.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (38)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta2.187
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
0
0
3-6months
0
112,900 shares
$149k
6-9months
0
3212,548 shares
$636k
9-12months
244,257 shares
$132k
140,000 shares
$149k